Shaun P. Brothers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shaun P. Brothers has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Claude-Henry Volmar
Center for Therapeutic Innovation University of Miami Miller School of Medicine Miami Florida USA
11 shared publications Jo Ann Janovick
Divisions of Neuroscience and Reproductive Sciences, Oregon National Primate Research Center, Beaverton, OR 97006, USA
11 shared publications- Claes Wahlestedt
University of Miami Miller School of Medicine
10 shared publications Claes Wahlestedt
Leonard m miller school of medicine
8 shared publications- P. Michael Conn
Oregon National Primate Research Center, Oregon Health and Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA
8 shared publications - Daniel Bilbao
Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
7 shared publications
Latest Publications
- Open Access
Identification of targetable epigenetic vulnerabilities for uveal melanoma
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, with a strong predilection for hepatic metastasis, occurring in approximately 50% of cases. Metastatic UM remains highly resistant to therapy and is almost invariably fatal. The strongest genetic drivers of UM metastasis are loss-of-function mutations in tumor suppressor BAP1 , an epigenetic regulator that serves as the ubiquitin hydrolase subunit of the polycomb repressive deubiquitinase (PR-DUB) complex, and a key player in global epigenetic regulation. Inactivation of BRCA Associated Protein 1 (BAP1) has been shown to induce widespread epigenetic alterations across multiple model systems. To identify novel therapeutic strategies, we investigated whether targeting the epigenome could reveal new vulnerabilities in UM. We performed high-throughput compound screening using a curated epigenetic inhibitor library and identified BET (bromodomain and extra-terminal domain) inhibition as a particularly promising approach. Interestingly, we observed significant heterogeneity in the efficacy of different BET inhibitors in UM. While previous clinical trials with two BET inhibitors have failed to show efficacy in UM, our findings highlight substantial differences in the potency of specific BET inhibitors for this malignancy. Notably, the BET inhibitor mivebresib (ABBV-075) significantly improved survival rates by 50% in a metastatic UM xenograft mouse model and completely prevented detectable metastases in the bones, spinal cord, and brain. Unexpectedly, RNA sequencing revealed a strong transcriptional overlap between BET inhibition and histone deacetylase (HDAC) inhibition--an approach currently under clinical evaluation for UM treatment. Both BET and HDAC inhibitors reversed gene expression signatures associated with high metastatic risk and induced a neuronal differentiation-like phenotype in UM cells. Together, our findings demonstrate that UM cells exhibit a distinct vulnerability to BET inhibition and establish BET inhibitors as promising candidates for further clinical evaluation for metastatic UM.
Open AccessIdentification of targetable epigenetic vulnerabilities for uveal melanoma
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, with a strong predilection for hepatic metastasis, occurring in approximately 50% of cases. Metastatic UM remains highly resistant to therapy and is almost invariably fatal. The strongest genetic drivers of UM metastasis are loss-of-function mutations in tumor suppressor BAP1 , an epigenetic regulator that serves as the ubiquitin hydrolase subunit of the polycomb repressive deubiquitinase (PR-DUB) complex, and a key player in global epigenetic regulation. Inactivation of BRCA Associated Protein 1 (BAP1) has been shown to induce widespread epigenetic alterations across multiple model systems. To identify novel therapeutic strategies, we investigated whether targeting the epigenome could reveal new vulnerabilities in UM. We performed high-throughput compound screening using a curated epigenetic inhibitor library and identified BET (bromodomain and extra-terminal domain) inhibition as a particularly promising approach. Interestingly, we observed significant heterogeneity in the efficacy of different BET inhibitors in UM. While previous clinical trials with two BET inhibitors have failed to show efficacy in UM, our findings highlight substantial differences in the potency of specific BET inhibitors for this malignancy. Notably, the BET inhibitor mivebresib (ABBV-075) significantly improved survival rates by 50% in a metastatic UM xenograft mouse model and completely prevented detectable metastases in the bones, spinal cord, and brain. Unexpectedly, RNA sequencing revealed a strong transcriptional overlap between BET inhibition and histone deacetylase (HDAC) inhibition--an approach currently under clinical evaluation for UM treatment. Both BET and HDAC inhibitors reversed gene expression signatures associated with high metastatic risk and induced a neuronal differentiation-like phenotype in UM cells. Together, our findings demonstrate that UM cells exhibit a distinct vulnerability to BET inhibition and establish BET inhibitors as promising candidates for further clinical evaluation for metastatic UM.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
Table S2. Results of epigenetic library screen.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
Table S2. Results of epigenetic library screen.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Material -Table Legends, Figures and Legends 1-3 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
S1. Doxycycline-inducible shRNA knockdown of BAP1 results in robust decrease of GLO1 expression in uveal melanoma cell lines. S2. Phenotypic rescue and toxicity analysis of three HDAC inhibitors in Xenopus embryos injected with control morpholino CtrlMO or bap1-targeting morpholino BAP1MO. S3. Quisinostat and trametinib combination exhibits mostly additive cytotoxic effect in uveal melanoma in vitro.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material -Table Legends, Figures and Legends 1-3 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
S1. Doxycycline-inducible shRNA knockdown of BAP1 results in robust decrease of GLO1 expression in uveal melanoma cell lines. S2. Phenotypic rescue and toxicity analysis of three HDAC inhibitors in Xenopus embryos injected with control morpholino CtrlMO or bap1-targeting morpholino BAP1MO. S3. Quisinostat and trametinib combination exhibits mostly additive cytotoxic effect in uveal melanoma in vitro.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
Table S1. Results of differential expression analysis
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
Table S1. Results of differential expression analysis
- Open Access
- 27 July 2022
- Published by Springer Nature in AAPS Open
- Vol. 8 (1) , 1-2
Correction: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)
- 27 July 2022
- Published by Springer Nature in AAPS Open
- Vol. 8 (1) , 1-2
Open AccessCorrection: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)
- Open Access
- 30 March 2019
- Published by Springer Nature in Molecular Cancer
- Vol. 18 (1) , 1-13
mRNA-to-protein translation in hypoxia
Cells respond to hypoxia by shifting cellular processes from general housekeeping functions to activating specialized hypoxia-response pathways. Oxygen plays an important role in generating ATP to maintain a productive rate of protein synthesis in normoxia. In hypoxia, the rate of the canonical protein synthesis pathway is significantly slowed and impaired due to limited ATP availability, necessitating an alternative mechanism to mediate protein synthesis and facilitate adaptation. Hypoxia adaptation is largely mediated by hypoxia-inducible factors (HIFs). While HIFs are well known for their transcriptional functions, they also play imperative roles in translation to mediate hypoxic protein synthesis. Such adaptations to hypoxia are often hyperactive in solid tumors, contributing to the expression of cancer hallmarks, including treatment resistance. The current literature on protein synthesis in hypoxia is reviewed here, inclusive of hypoxia-specific mRNA selection to translation termination. Current HIF targeting therapies are also discussed as are the opportunities involved with targeting hypoxia specific protein synthesis pathways.
- 30 March 2019
- Published by Springer Nature in Molecular Cancer
- Vol. 18 (1) , 1-13
Open AccessmRNA-to-protein translation in hypoxia
Cells respond to hypoxia by shifting cellular processes from general housekeeping functions to activating specialized hypoxia-response pathways. Oxygen plays an important role in generating ATP to maintain a productive rate of protein synthesis in normoxia. In hypoxia, the rate of the canonical protein synthesis pathway is significantly slowed and impaired due to limited ATP availability, necessitating an alternative mechanism to mediate protein synthesis and facilitate adaptation. Hypoxia adaptation is largely mediated by hypoxia-inducible factors (HIFs). While HIFs are well known for their transcriptional functions, they also play imperative roles in translation to mediate hypoxic protein synthesis. Such adaptations to hypoxia are often hyperactive in solid tumors, contributing to the expression of cancer hallmarks, including treatment resistance. The current literature on protein synthesis in hypoxia is reviewed here, inclusive of hypoxia-specific mRNA selection to translation termination. Current HIF targeting therapies are also discussed as are the opportunities involved with targeting hypoxia specific protein synthesis pathways.
- Open Access
- 1 February 2016
- Published by Elsevier in Cell Reports
- Vol. 14 (6) , 1293-1300
Systemic Reprogramming of Translation Efficiencies on Oxygen Stimulus
- 1 February 2016
- Published by Elsevier in Cell Reports
- Vol. 14 (6) , 1293-1300
Open AccessSystemic Reprogramming of Translation Efficiencies on Oxygen Stimulus